Diet, nutrients and metabolism: Cogs in the wheel driving Alzheimer's disease pathology?
Alzheimer's disease (AD), the most common form of dementia, is a chronic, progressive neurodegenerative disease that manifests clinically as a slow global decline in cognitive function, including deterioration of memory, reasoning, abstraction, language and emotional stability, culminating in a...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Cambridge University Press
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/61638 |
| _version_ | 1848760700270280704 |
|---|---|
| author | Creegan, Rhona Hunt, Wendy McManus, Alexandra Rainey-Smith, S. |
| author_facet | Creegan, Rhona Hunt, Wendy McManus, Alexandra Rainey-Smith, S. |
| author_sort | Creegan, Rhona |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Alzheimer's disease (AD), the most common form of dementia, is a chronic, progressive neurodegenerative disease that manifests clinically as a slow global decline in cognitive function, including deterioration of memory, reasoning, abstraction, language and emotional stability, culminating in a patient with end-stage disease, totally dependent on custodial care. With a global ageing population, it is predicted that there will be a marked increase in the number of people diagnosed with AD in the coming decades, making this a significant challenge to socio-economic policy and aged care. Global estimates put a direct cost for treating and caring for people with dementia at $US604 billion, an estimate that is expected to increase markedly. According to recent global statistics, there are 35.6 million dementia sufferers, the number of which is predicted to double every 20 years, unless strategies are implemented to reduce this burden. Currently, there is no cure for AD; while current therapies may temporarily ameliorate symptoms, death usually occurs approximately 8 years after diagnosis. A greater understanding of AD pathophysiology is paramount, and attention is now being directed to the discovery of biomarkers that may not only facilitate pre-symptomatic diagnosis, but also provide an insight into aberrant biochemical pathways that may reveal potential therapeutic targets, including nutritional ones. AD pathogenesis develops over many years before clinical symptoms appear, providing the opportunity to develop therapy that could slow or stop disease progression well before any clinical manifestation develops. |
| first_indexed | 2025-11-14T10:19:56Z |
| format | Journal Article |
| id | curtin-20.500.11937-61638 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:19:56Z |
| publishDate | 2015 |
| publisher | Cambridge University Press |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-616382019-02-19T05:36:14Z Diet, nutrients and metabolism: Cogs in the wheel driving Alzheimer's disease pathology? Creegan, Rhona Hunt, Wendy McManus, Alexandra Rainey-Smith, S. Alzheimer's disease (AD), the most common form of dementia, is a chronic, progressive neurodegenerative disease that manifests clinically as a slow global decline in cognitive function, including deterioration of memory, reasoning, abstraction, language and emotional stability, culminating in a patient with end-stage disease, totally dependent on custodial care. With a global ageing population, it is predicted that there will be a marked increase in the number of people diagnosed with AD in the coming decades, making this a significant challenge to socio-economic policy and aged care. Global estimates put a direct cost for treating and caring for people with dementia at $US604 billion, an estimate that is expected to increase markedly. According to recent global statistics, there are 35.6 million dementia sufferers, the number of which is predicted to double every 20 years, unless strategies are implemented to reduce this burden. Currently, there is no cure for AD; while current therapies may temporarily ameliorate symptoms, death usually occurs approximately 8 years after diagnosis. A greater understanding of AD pathophysiology is paramount, and attention is now being directed to the discovery of biomarkers that may not only facilitate pre-symptomatic diagnosis, but also provide an insight into aberrant biochemical pathways that may reveal potential therapeutic targets, including nutritional ones. AD pathogenesis develops over many years before clinical symptoms appear, providing the opportunity to develop therapy that could slow or stop disease progression well before any clinical manifestation develops. 2015 Journal Article http://hdl.handle.net/20.500.11937/61638 10.1017/S0007114515000926 Cambridge University Press fulltext |
| spellingShingle | Creegan, Rhona Hunt, Wendy McManus, Alexandra Rainey-Smith, S. Diet, nutrients and metabolism: Cogs in the wheel driving Alzheimer's disease pathology? |
| title | Diet, nutrients and metabolism: Cogs in the wheel driving Alzheimer's disease pathology? |
| title_full | Diet, nutrients and metabolism: Cogs in the wheel driving Alzheimer's disease pathology? |
| title_fullStr | Diet, nutrients and metabolism: Cogs in the wheel driving Alzheimer's disease pathology? |
| title_full_unstemmed | Diet, nutrients and metabolism: Cogs in the wheel driving Alzheimer's disease pathology? |
| title_short | Diet, nutrients and metabolism: Cogs in the wheel driving Alzheimer's disease pathology? |
| title_sort | diet, nutrients and metabolism: cogs in the wheel driving alzheimer's disease pathology? |
| url | http://hdl.handle.net/20.500.11937/61638 |